Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

CalciMedica Inc CALC

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).


NDAQ:CALC - Post by User

Post by alphaflighton May 19, 2021 12:08pm
887 Views
Post# 33230283

Graycliff Exploration Drills 67 g/t Au Over 3M Near Surface

Graycliff Exploration Drills 67 g/t Au Over 3M Near Surface
Graycliff Exploration Drills 67 g/t Gold
Over 3.0 Metres Near Surface
TORONTO, ON - May 19, 2021 -  Graycliff Exploration Limited (the “Company” or “Graycliff”) (CSE: GRAY) (OTCQB: GRYCF) (FSE: GE0) is pleased to announce limited assay results of the first drill hole of its over 2,000 metre (“m”) phase two core drilling program (see Press Release dated April 22, 2021) on the Company’s Shakespeare Gold Project located on the prolific Canadian Shield near Sudbury, Ontario.
 
Drill Hole J-8-21 intersected a mineralized interval of 66.98 g/t gold (“Au”) over 3.0 m, as detailed below:
“While the Company is not in the practice of releasing partial results from its drill holes, the results received were significant enough to warrant their immediate release. We are optimistic that the results from the additional samples from hole J-8-21 that are currently at the lab will be available in the near future. Obviously, more than 2 ounces per ton over 3 metres is an exceptional start for our phase two drilling program,” stated President and CEO, James Macintosh.
 
This high-grade gold intersection in drill hole J-8-21 is located approximately 30 m down-dip of the mineralization reported from drill hole J-7-20 that highlighted an interval grading 8.59 g/t Au over 5.5m (see Cross Section “A-A” in Press Release dated March 24, 2021). Sample materials from several other drill holes have been delivered to the assay lab and those assay results are expected to be available in somewhat regular intervals over the coming weeks.
About Graycliff Exploration Limited.
Graycliff Exploration is a mineral exploration company focused on its 847 hectares of prospective ground, located roughly 80 kilometres west of Sudbury on the prolific Canadian Shield. The Company's Shakespeare Project consists of 39 claims on a property associated with the historic Shakespeare Gold Mine, which operated from 1903 to 1907. 
For more information, contact investor relations at investors@graycliffexploration.com
 
On Behalf of the Board of Directors,
 
James Macintosh
President and CEO
Graycliff Exploration Limited

<< Previous
Bullboard Posts
Next >>